MA56043A - Dérivés hétérocycliques fusionnés - Google Patents
Dérivés hétérocycliques fusionnésInfo
- Publication number
- MA56043A MA56043A MA056043A MA56043A MA56043A MA 56043 A MA56043 A MA 56043A MA 056043 A MA056043 A MA 056043A MA 56043 A MA56043 A MA 56043A MA 56043 A MA56043 A MA 56043A
- Authority
- MA
- Morocco
- Prior art keywords
- fused heterocyclic
- heterocyclic derivatives
- derivatives
- fused
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933 | 2019-05-28 | ||
| CN2020085720 | 2020-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56043A true MA56043A (fr) | 2022-04-06 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056043A MA56043A (fr) | 2019-05-28 | 2020-05-27 | Dérivés hétérocycliques fusionnés |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| AR124222A1 (es) * | 2020-12-02 | 2023-03-01 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| US20240279227A1 (en) * | 2021-06-02 | 2024-08-22 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| AR126049A1 (es) | 2021-06-02 | 2023-09-06 | Janssen Sciences Ireland Unlimited Co | Derivados heterocíclicos condensados |
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| WO2016109684A2 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| EP3478692B1 (en) * | 2016-06-29 | 2020-06-17 | Novira Therapeutics Inc. | Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections |
| BR112021021564A2 (pt) * | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000230A (es) | 2022-05-31 |
| BR112021022889A2 (pt) | 2022-01-04 |
| CL2021003155A1 (es) | 2022-07-22 |
| WO2020243135A1 (en) | 2020-12-03 |
| SG11202113167QA (en) | 2021-12-30 |
| CA3138168A1 (en) | 2020-12-03 |
| PH12021552974A1 (en) | 2022-07-11 |
| IL288322A (en) | 2022-01-01 |
| JP2022535734A (ja) | 2022-08-10 |
| CN113906028A (zh) | 2022-01-07 |
| KR20220012913A (ko) | 2022-02-04 |
| JOP20210313A1 (ar) | 2021-11-25 |
| BR112021022889A8 (pt) | 2024-03-05 |
| PE20220767A1 (es) | 2022-05-16 |
| MX2021014575A (es) | 2022-05-24 |
| CR20210666A (es) | 2022-03-11 |
| CO2021016433A2 (es) | 2021-12-10 |
| EP3976617B1 (en) | 2025-04-23 |
| EP3976617A1 (en) | 2022-04-06 |
| AU2020285718A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283333A (en) | New heterocyclic compounds | |
| PT3958977T (pt) | Derivados de camptotecina | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| MA56043A (fr) | Dérivés hétérocycliques fusionnés | |
| EP4013751C0 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| IL279977A (en) | Anthelminthic heterocyclic compounds | |
| EP4061813C0 (en) | PYRROLIDINE DERIVATIVES | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| EP4010076C0 (en) | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| PL4301748T3 (pl) | Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu | |
| ZA202106024B (en) | Heterocyclic derivatives | |
| EP3884940A4 (en) | Novel imidazole derivative | |
| DK3898637T3 (da) | Rapamycin-derivater | |
| PL3921307T3 (pl) | Pochodne pirazolu | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| EP3813522C0 (en) | TAUOPATHY MODELS | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| IL304774A (en) | Enhanced sophorolipid derivatives | |
| EP3822270A4 (en) | NEW HETEROCYCLIC DERIVATIVE | |
| DK3782986T3 (da) | Heterocyklisk forbindelse | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| DK4396183T3 (da) | Substituerede s-alaninatderivater |